ABSTRACT
Silicosis is an occupational pulmonary fibrosis caused by inhalation of silica (SiO2) and there are no ideal drugs to treat this disease. Earthworm extract (EE), a natural nutrient, has been reported to have anti-inflammatory, antioxidant, and anti-apoptosis effects. The purpose of the current study was to test the protective effects of EE against SiO2-induced pulmonary fibrosis and to explore the underlying mechanisms using both in vivo and in vitro models. We found that treatment with EE significantly reduced lung inflammation and fibrosis and improved lung structure and function in SiO2-instilled mice. Further mechanistic investigations revealed that EE administration markedly inhibited SiO2-induced oxidative stress, mitochondrial apoptotic pathway, and epithelial-mesenchymal transition in HBE and A549 cells. Furthermore, we demonstrate that Nrf2 activation partly mediates the interventional effects of EE against SiO2-induced pulmonary fibrosis. Our study has identified EE to be a potential anti-oxidative, anti-inflammatory, and anti-fibrotic drug for silicosis.
Subject(s)
Antioxidants/therapeutic use , Disease Models, Animal , Lung/drug effects , Materia Medica/therapeutic use , Oligochaeta/chemistry , Pulmonary Fibrosis/prevention & control , Silicosis/drug therapy , Tissue Extracts/therapeutic use , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antioxidants/administration & dosage , Antioxidants/pharmacology , Apoptosis/drug effects , Cell Line , Cells, Cultured , Epithelial-Mesenchymal Transition/drug effects , Injections, Intraperitoneal , Lung/metabolism , Lung/pathology , Lung/physiopathology , Male , Materia Medica/administration & dosage , Materia Medica/pharmacology , Mice, Inbred C57BL , NF-E2-Related Factor 2/agonists , NF-E2-Related Factor 2/antagonists & inhibitors , NF-E2-Related Factor 2/genetics , NF-E2-Related Factor 2/metabolism , Oxidative Stress/drug effects , Pulmonary Fibrosis/etiology , Pulmonary Fibrosis/immunology , RNA Interference , Random Allocation , Respiratory Mucosa/cytology , Respiratory Mucosa/drug effects , Respiratory Mucosa/metabolism , Respiratory Mucosa/pathology , Silicosis/metabolism , Silicosis/pathology , Silicosis/physiopathology , Specific Pathogen-Free Organisms , Tissue Extracts/administration & dosage , Tissue Extracts/pharmacologyABSTRACT
BACKGROUND: M1 is a homeopathic medicine with immunostimulatory properties used mainly by cancer patients to complement current therapies. Metastatic melanoma is a skin-originated form of cancer without a single therapy able to produce high rate and sustained responses, which attracts the use of complementary therapies such as M1. However, M1's anti-melanoma effects remain to be pre-clinically demonstrated. Therefore in the present work, we utilized a pulmonary metastatic melanoma model and a subcutaneous melanoma growth model to investigate the potential benefits of treatment with M1. METHODS: C57BL/6 mice were injected intravenously or subcutaneously with B16F10 mouse melanoma cells. After 24 h, mice were treated with either M1 or vehicle (water) for 14 days, euthanized and harvested for multi-parameter pulmonary and tumor analyses. RESULTS: Mice treated with M1 had significantly lower tumor burden in the lungs and subcutaneous tissue than control mice. Furthermore, tumors were impaired in proliferation and tumor related angiogenesis by the inhibition of myeloid derived suppressor cells (MDSC) positive for angiotensin II type 1 receptor (AT1R). CONCLUSION: Altogether these data suggest M1 is an efficient candidate for melanoma therapy to be considered for future clinic studies as this study is the first supporting the idea that melanoma patients may benefit with the treatment. The treatment with M1 provides advantages considering the highly-diluted properties and a cost effective alternative to costly chemotherapeutic approaches with, if any, lower toxicity.
Subject(s)
Homeopathy/methods , Materia Medica/therapeutic use , Melanoma/drug therapy , Melanoma/prevention & control , Respiratory Therapy/methods , Animals , Disease Models, Animal , Mice , Mice, Inbred C57BLABSTRACT
The property theory is a unique principle instructing traditional Chinese doctors to prescribe proper medicines against diseases. As an essential part of it, the five-flavor theory catalogs various Chinese materia medicas (CMMs) into five flavors (sweet, bitter, sour, salty, and pungent) based on their taste and medical functions. Although CMM has been successfully applied in China for thousands of years, it is still a big challenge to interpret CMM flavor via modern biomarkers, further deepening its elusiveness. Herein, to identify the correlation between gut microbiota and CMM flavor, we selected 14 CMMs with different flavors to prepare their aqueous extracts, quantified the contained major chemical components, and then performed full-length 16S rRNA sequencing to analyze the gut microbiota of C57BL/6 mice administrated with CMM extracts. We found that flavones, alkaloids, and saponins were the richest components for sweet-, bitter-, and pungent-flavored CMMs, respectively. Medicines with merged flavors (bitter-pungent and sweet-pungent) displayed mixed profiles of components. According to gut microbial analysis, modulation of CMMs belonging to the same flavor on the taxonomic classification was inconsistent to an extent, while the functional sets of gut microbiota, co-abundance gene groups (CAGs), strongly and differentially responded to distinct flavors. Moreover, these correlations were in line with their pharmacological actions. Therefore, the gut microbial functional sets (CAGs) could act as the possible indicator to reflect CMM flavor, rather than the composition of microbial community.
Subject(s)
Gastrointestinal Microbiome , Materia Medica , Mice , Animals , Medicine, Chinese Traditional , Gastrointestinal Microbiome/genetics , RNA, Ribosomal, 16S/genetics , Mice, Inbred C57BLABSTRACT
BACKGROUND: Toxicodendron pubescens is a botanical name of Rhus toxicodendron (Rhus tox). This plant is widely used in its homeopathically diluted form in the treatment of inflammatory and edematous conditions. In this study, various dilutions of Rhus tox including its crude form have been evaluated for their effects on immune response in the in vivo and in vitro experimental models. METHODS: Rhus tox in the form of mother tincture, 6cH, 30cH, 200cH and 1000cH dilutions was tested through in vivo models including sheep red blood cells (SRBCs) induced cellular and humoral immune response in C57/BL6 mice. The effects of Rhus tox dilutions were also evaluated in vitro on the functions of human polymorphonuclear (PMN) cells such as phagocytosis and intracellular killing of Candida albicans, chemotaxis, and reduction of nitroblue tetrazolium (NBT) dye. RESULTS: Rhus tox was found to intensify SRBCs induced antibody titer and delayed type hypersensitivity response in mice. Even higher dilutions such as 200cH and 1000cH were found to affect the immune response; however, the crude form, mother tincture, 6cH and 30cH dilutions revealed more potent effects than the 200cH and 1000cH dilutions. In in vitro assays, all the dilutions exerted stimulation of phagocytosis, candidacidal activity and chemotaxis of human PMN cells. The NBT dye reduction assay revealed that oxidative processes in the PMN cells are accelerated in the presence of Rhus tox. This study shows that Rhus tox possesses immunostimulatory activity in its crude form as well as in homeopathically diluted forms. These effects appeared to be concentration dependent as higher dilutions had less potent effects.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Homeopathy/methods , Immunologic Factors/pharmacology , Toxicodendron , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Immunity, Cellular/drug effects , Mice , Mice, Inbred C57BL , Phytotherapy , Plant Extracts/pharmacologyABSTRACT
AIM: The aim of this study was to evaluate the action of homeopathic treatment on mice experimentally infected with Trypanosoma cruzi. METHODS: Eighty adult male C57BL/6 inbred mice were randomly allocated to five groups treated with biotherapy (nosode) of T. cruzi 12dH (12x) pre- and post-infection; Phosphorus 12dH post-infection; infected control treated with control solution and uninfected control. The biotherapy was prepared by the Costa method from the blood of mice experimentally infected with the Y strain of T. cruzi. Phosphorus was used because of its clinical and reportorial similarity to Chagas disease. T. cruzi (10(4)) sanguineous forms were inoculated intraperitoneally per animal. Parasitaemia was monitored, leukocyte and serological responses were evaluated at 0, 7, 14 and 42 days after infection. The prepatent and patent periods of parasitaemia, maximum of parasitaemia, day of maximum parasitaemia and mortality rates were compared between groups. RESULTS: A significantly shorter period of patent parasitaemia was observed in the group treated with the biotherapy before infection (p<0.05) than in the other groups. This group also had the lowest parasitaemias values at 9, 13, 15 (p<0.05), 17 (p<0.05), 22, 24 and 28 days, a lower rate of mortality and a significant increase of lymphocytes compared to the infected control group. The Phosphorus group had the longest period of patent parasitaemia, higher maximum parasitaemia, and a significant reduction of lymphocyte numbers, but no mortality. The infected control group had the highest mortality rate (not statistically significant), and the highest IgG titres at 42 days post-infection (p<0.05). CONCLUSIONS: The results suggest that pre-treatment with biotherapy modulates host immune response to T. cruzi, mainly during the acute phase of the infection. Phosphorus shows an action on the pathogenicity by T. cruzi infection. Homeopathic treatment of T. cruzi infection should be further investigated.
Subject(s)
Chagas Disease/drug therapy , Homeopathy/methods , Parasitemia/drug therapy , Phosphorus/pharmacology , Phytotherapy/methods , Plant Extracts/therapeutic use , Trypanosoma cruzi/drug effects , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Mice , Mice, Inbred C57BL , Parasitemia/virology , Plant Extracts/pharmacology , Random AllocationABSTRACT
OBJECTIVE: To evaluate the therapy action of Sal-Ammoniac extract on Lewis lung cancer and its toxicity to immunity. METHODS: The proliferation and cell cycle of Lewis lung cancer cells were determined by MTT assay and flow cytometry respectively. The antitumor effect of Sal-Ammoniac extract was observed by tumor injected subcutaneously in mice and its toxicity to immunity was examined by clearance rate of charcoal particles and delayed type hypersensitivity. RESULTS: Sal-Ammoniac extract could inhibit the proliferation of Lewis lung cancer cells with S cell cycle arrest in a dose-dependent manner in vitro. Sal-Ammoniac extract solution injected in tumor for eight days had 46.7% inhibition on Lewis lung cancer, if taken orally had only 15.7% inhibition on Lewis lung cancer in mice. Sal-Ammoniac extract solution injected subcutaneously or taken orally had no effect on the clearance rate of charcoal particles and delayed type hypersensitivity in mice. CONCLUSION: The antitumor action of Sal-Ammoniac extract has relation to its recipe and has no influence on immunity.
Subject(s)
Ammonium Chloride/pharmacology , Antineoplastic Agents/pharmacology , Carcinoma, Lewis Lung/drug therapy , Materia Medica/pharmacology , Ammonium Chloride/administration & dosage , Animals , Antineoplastic Agents/administration & dosage , Carcinoma, Lewis Lung/pathology , Cell Cycle/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Female , Flow Cytometry , Materia Medica/administration & dosage , Mice , Mice, Inbred C57BLABSTRACT
Traditional Chinese medicine is one of the oldest medical systems in the world and has its unique principles and theories in the prevention and treatment of human diseases, which are achieved through the interactions of different types of materia medica in the form of Chinese medicinal formulations. GZZSZTW, a classical and effective Chinese medicinal formulation, was designed and created by professor Bailing Liu who is the only national medical master professor in the clinical research field of traditional Chinese medicine and skeletal diseases. GZZSZTW has been widely used in clinical settings for several decades for the treatment of joint diseases. However, the underlying molecular mechanisms are still largely unknown. In the present study, we performed quantitative proteomic analysis to investigate the effects of GZZSZTW on mouse primary chondrocytes using state-of-the-art iTRAQ technology. We demonstrated that the Chinese medicinal formulation GZZSZTW modulates chondrocyte structure, dynamics, and metabolism by controlling multiple functional proteins that are involved in the cellular processes of DNA replication and transcription, protein synthesis and degradation, cytoskeleton dynamics, and signal transduction. Thus, this study has expanded the current knowledge of the molecular mechanism of GZZSZTW treatment on chondrocytes. It has also shed new light on possible strategies to further prevent and treat cartilage-related diseases using traditional Chinese medicinal formulations.
Subject(s)
Biological Products/pharmacology , Chondrocytes/drug effects , Chondrocytes/metabolism , Drugs, Chinese Herbal/pharmacology , Proteins/metabolism , Animals , DNA Replication/drug effects , Materia Medica/pharmacology , Medicine, Chinese Traditional/methods , Mice , Mice, Inbred C57BL , Proteomics/methods , Signal Transduction/drug effects , Transcription, Genetic/drug effectsABSTRACT
Ultra low doses used in homeopathic medicines are reported to have healing potential for various diseases but their action remains controversial. In this study we have investigated the antitumour and antimetastatic activity of selected homeopathic medicines against transplanted tumours in mice. It was found that Ruta graveolens 200c and Hydrastis canadensis 200c significantly increased the lifespan of Ehrlich Ascites Carcinoma and Dalton's Lymphoma Ascites induced tumour-bearing animals by 49.7%, and 69.4% respectively. Moreover there was 95.6% and 95.8% reduction of solid tumour volume in Ruta 200c and Hydrastis 200c treated animals on the 31st day after tumour inoculation. Hydrastis 1M given orally significantly inhibited the growth of developed solid tumours produced by DLA cells and increased the lifespan of tumour bearing animals. Some 9 out of 15 animals with developed tumors were completely tumour free after treatment with Hydrastis 1M. Significant anti-metastatic activity was also found in B16F-10 melanoma-bearing animals treated with Thuja1M, Hydrastis 1M and Lycopodium1M. This was evident from the inhibition of lung tumour nodule formation, morphological and histopathological analysis of lung and decreased levels of gamma-GT in serum, a cellular marker of proliferation. These findings support that homeopathic preparations of Ruta and Hydrastis have significant antitumour activity. The mechanism of action of these medicines is not known at present.
Subject(s)
Homeopathy , Neoplasms/drug therapy , Plant Extracts/therapeutic use , Animals , Hydrastis , Lycopodium , Melanoma/secondary , Melanoma/therapy , Mice , Mice, Inbred C57BL , Mice, Inbred Strains , Neoplasm Metastasis/prevention & control , Ruta , ThujaABSTRACT
Among the numerous agents tested on melanoma, cytokines have attracted much attention over recent decades, in particular interferon-alpha (IFN-alpha). However, in a small number of experimental assays, homeopathic products have also been used. This study aimed to analyze the effects of INF-alpha and Lymphomyosot, administered individually or in combination, on the growth of B16F10 melanoma transplanted in C57BL/6J mice. Two experiments were performed using 72 young male mice, treated with 1 x 10(6) B16F10 cells and treated with phosphate-buffered saline (I), INF-alpha (II), Lymphomyosot (III), and both INF-alpha and Lymphomyosot (IV). Subsequent morphological and immunohistochemical studies were performed. All treatments produced a reduction in tumor weight with significant differences in those treated with INF-alpha and Lymphomyosot. INF-alpha reduced the cell proliferation index and the spread of inflammatory infiltrates and produced an increase in the extent of intratumoral necrosis. An antitumour effect was displayed by both agents, as was the cytotoxicity of INF-alpha and the immune response-stimulating effect of Lymphomyosot.
Subject(s)
Interferon-alpha/administration & dosage , Materia Medica/administration & dosage , Melanoma/drug therapy , Plant Extracts/administration & dosage , Animals , Cell Line, Tumor , Cell Proliferation/drug effects , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Therapy, Combination , Humans , Immunohistochemistry , Inflammation/drug therapy , Inflammation/pathology , Infusions, Intravenous , Interferon-alpha/therapeutic use , Male , Materia Medica/therapeutic use , Melanoma/pathology , Mice , Mice, Inbred C57BL , Necrosis/drug therapy , Necrosis/pathology , Neoplasms, Experimental/pathology , Plant Extracts/therapeutic use , Treatment Outcome , Xenograft Model Antitumor AssaysABSTRACT
OBJECTIVE: To investigate the mechanisms of tumor inhibiting and immunoloregulation of Mylabris Mixture on H22 cancer-bearing mice. METHODS: H22 cancer-bearing mice were chosen to observe the effects of tumor inhibiting and detect the proliferation function of T lymphocytes, the toxicity function of NK cells, the changes of T lymphocytes and the contents of interferon-gamma and interleukin-4. RESULTS: Mylabris Mixture could obviously inhibit the growth of H22 cancer in mice, and the tumor inhibition rat was 65.76%. The stimulation index of T lymphocyte transformation and percentage of NK cells in Mylabris Mixture-treated group were obviously higher than those in the normal control group. The subpopulation proportion of T lymphocytes in Mylabris Mixture-treated group was changed more than the normal control group. The production of interferon-gamma and interleukin-4 by T lymphocytes obviously increased in Mylabris Mixture-treated group (P<0.05, P<0.001). CONCLUSION: Mylabris Mixture has the effect of inhibiting the growth of tumor constitution, and regulating immunological function on mice with tumor. Its mechanisms include the reinforcement of T lymphocyte immune function, NK cell killing function and humoral immune function.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Coleoptera/chemistry , Liver Neoplasms, Experimental/drug therapy , Liver Neoplasms, Experimental/immunology , Animals , Antineoplastic Agents/administration & dosage , Cell Line, Tumor , Cytotoxicity Tests, Immunologic , Cytotoxicity, Immunologic/drug effects , Drugs, Chinese Herbal/administration & dosage , Humans , K562 Cells , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Liver Neoplasms, Experimental/pathology , Male , Materia Medica , Mice , Mice, Inbred C57BL , Random Allocation , T-Lymphocytes/drug effects , T-Lymphocytes/immunologyABSTRACT
Homeopathic remedies have been selectively employed in human medicine since Hahneman introduced the concept in 1828. While the use of homeopathy is regionally popular in both human and veterinary medicine, there is still a significant lack of scientific evidence supporting its efficacy. This is likely due to an absence of studies evaluating the mechanism of action of these compounds. Engystol® an FDA-approved antiviral agent, is a popular homeopathic commercial product. In select in vivo and in vitro observational studies, the drug showed a measureable innate immune therapeutic efficacy. The focus of the present study was to evaluate the innate and adaptive immunomodulatory effects of oral Engystol(®) (1 or 10 tablets/L water consumed), prior to and post antigenic challenge in a mouse model with a well-characterized and clinically measureable immune system. We first evaluated the murine immune response when oral Engystol(®) was given alone for 28days. Mice were then challenged with an antigen-specific H5N1 HA vaccine while on Engystol(®) for an additional 33days. Serum and supernatants from cultured splenic lymphocytes were collected and screened with a 32-cytokine panel. Serum vaccine epitope-specific IgG titers plus T cell and B cell phenotypes from splenic tissue were also evaluated. Preliminary results showed that Engystol(®) alone did not alter immunity; however, upon vaccine challenge, Engystol(®) decreased CD4(+)/CD8(+) ratios, altered select cytokines/chemokines, and anti-H5N1 HA IgG titers were increased in the 10 tablet/L group. Collectively, these data suggest that Engystol(®) can modulate immunity upon antigenic challenge.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Influenza A Virus, H5N1 Subtype/immunology , Influenza Vaccines/immunology , Influenza, Human/prevention & control , Orthomyxoviridae Infections/prevention & control , Plant Extracts/administration & dosage , Th1 Cells/immunology , Animals , Antibodies, Viral/blood , CD4-CD8 Ratio , Female , Hemagglutinin Glycoproteins, Influenza Virus/immunology , Humans , Immunity, Innate , Immunologic Factors , Immunophenotyping , Influenza, Human/immunology , Mice , Mice, Inbred C57BL , Orthomyxoviridae Infections/immunologyABSTRACT
We aimed to investigate the effect of perioperative analgesia with nonselective cyclooxygenase-2 inhibitor dexketoprofen and opioid drug omnopon on the functional activity of immune cells in tumor excision murine model. Lewis lung carcinoma cells were transplanted into hind paw of C57/black mice. On the 23th day tumor was removed. Analgesic drugs were injected 30 min before and once a day for 3 days after the surgery. Biological material was obtained a day before, 1 day and 3 days after the tumor removal. IFN-γ, IL-4, IL-10 and TGF-ß mRNA levels in splenic cells were assessed by quantitative real-time RT-PCR. Cytotoxic activity of splenocytes was estimated by flow cytometry. We found that in splenocytes of mice received opioid analgesia IL-10 mRNA level was increased 2.3 times on day one after the surgery compared to preoperative level (P < 0.05), while in dexketoprofen group this parameter did not change. IFN-γ gene expression level on day 3 after tumor removal was 40% higher in splenocytes of dexketoprofen treated mice as compared with omnopon treated animals (P < 0.05). Cytotoxic activity of splenocytes on day 3 postsurgery was (62.2 ± 2.4)% in dexketoprofen against (50.2 ± 3.3)% in omnopon group. In conclusion, perioperative analgesia with cyclooxygenase inhibitor dexketoprofen in contrast to opioid analgesia with omnopon preserves higher functional activity of murine immune cells in the experimental model of tumor surgery.
Subject(s)
Analgesics/pharmacology , Carcinoma, Lewis Lung/immunology , Cytotoxicity, Immunologic/drug effects , Ketoprofen/pharmacology , Lymphocytes/drug effects , Opium/pharmacology , Pain, Procedural/prevention & control , Animals , Carcinoma, Lewis Lung/genetics , Carcinoma, Lewis Lung/pathology , Carcinoma, Lewis Lung/surgery , Gene Expression , Hindlimb , Interferon-gamma/genetics , Interferon-gamma/immunology , Interleukin-10/genetics , Interleukin-10/immunology , Interleukin-4/genetics , Interleukin-4/immunology , Ketoprofen/analogs & derivatives , Lymphocytes/cytology , Lymphocytes/immunology , Mice , Mice, Inbred C57BL , Neoplasm Transplantation , Pain, Procedural/immunology , Pain, Procedural/physiopathology , Perioperative Period , RNA, Messenger/genetics , RNA, Messenger/immunology , Spleen/cytology , Spleen/drug effects , Spleen/immunology , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/immunologyABSTRACT
OBJECTIVE: To observe the pharmacodynamic and side effects of Wulong Kangai, a new drug of Chinese traditional herbal medicine, on 4 strains of mice transplantable tumors. METHOD: Mice transplantable tumors S180, H22, P388 and Lewis were used in the pharmacodynamic test on the granules of Wulong Kangai. The test on each tumor strain was repeated three times. In each test, 50 mice were used and divided into 5 groups. They were negative control group treated by physiological saline, cyclophosphamide control group and 3 test groups treated respectively with Wulong Kangai at deferent dosages of 10, 25, 40 g x kg(-1) x d(-1) in the treatment of Lewis and P388 and 15, 30, 50 g x kg(-1) x d(-1) in the treatment of S180 and H22. RESULT: The tumor weight were inhibited at the rates of 90.1%, 30.8%, 49.8% and 52. 3% in the mice with tumors of Lewis, P388, S180, and H22 by high dosage of Wulong Kangai as compared with negative control group. The inhibitory rates in cyclophosphamide groups were 90.6%, 77.2%, 79.6% and 60.3% respectively. The mice body weights grew slower in high dose groups treated by Wulong Kangai granule. CONCLUSION: Wulong Kangai was effective in treating mice transplantable tumors of Lewis, P388, S180 and H22 with a dose-dependent manner. The Lewis was the most sensitive strain to the drug among the 4 kinds of tested tumors. Side effects appeared during 9-11 days of uninterrupted treatment with high dose Wulong Kangai.
Subject(s)
Antineoplastic Agents/pharmacology , Drugs, Chinese Herbal/pharmacology , Materia Medica/pharmacology , Neoplasms, Experimental/pathology , Animals , Antineoplastic Agents/toxicity , Arthropods/chemistry , Carcinoma, Lewis Lung/pathology , Cell Line, Tumor , Dose-Response Relationship, Drug , Drugs, Chinese Herbal/isolation & purification , Drugs, Chinese Herbal/toxicity , Female , Leukemia P388/pathology , Liver Neoplasms, Experimental/pathology , Male , Materia Medica/isolation & purification , Materia Medica/toxicity , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Neoplasm Transplantation , Plants, Medicinal/chemistry , Sarcoma 180/pathologyABSTRACT
Earlier results on the existence of genes affecting variability are revisited in the context of effects of phase-shifts on lifespan.
Subject(s)
Biological Clocks/genetics , Genetic Variation , Homeostasis/genetics , Longevity/genetics , Models, Biological , Animals , Mice , Mice, Inbred C57BL/genetics , Mice, Inbred DBA/genetics , Time Factors , VitalismABSTRACT
Experiments on animals with transplanted tumors (Lewis lung carcinoma and carcinosarcoma Walker-256) showed that combination treatment with cyclophosphane and its homeopathically potentiated forms increases antiblastic activity of the preparation.
Subject(s)
Antineoplastic Agents, Alkylating/pharmacology , Cyclophosphamide/pharmacology , Homeopathy/methods , Animals , Carcinoma 256, Walker/pathology , Carcinoma, Lewis Lung/pathology , Cytostatic Agents/pharmacology , Female , Mice , Mice, Inbred C57BL , Neoplasm Transplantation , RatsABSTRACT
Antibodies to cyclophosphamide obtained by homeopathic potentiation and administered in ultralow doses exhibit no antiblastic activity and did not modulate the effectiveness of cyclophosphamide during antitumor therapy of animals with transplanted tumors (Lewis lung carcinoma and Ehrlich adenocarcinoma).
Subject(s)
Antibodies/therapeutic use , Antineoplastic Agents, Alkylating/therapeutic use , Carcinoma, Ehrlich Tumor/drug therapy , Carcinoma, Lewis Lung/drug therapy , Cyclophosphamide/immunology , Cyclophosphamide/therapeutic use , Cytostatic Agents/therapeutic use , Animals , Antibodies/immunology , Dose-Response Relationship, Drug , Mice , Mice, Inbred C57BL , Neoplasms, Experimental/drug therapyABSTRACT
As a kind of anti-inflammatory protein fractionated and purified from the larva of parasa sinica, CCP (ip) has a significant anti-inflammatory effect on ear odema induced by croton oil in mice. Its ID50 is 1.6mg/kg, but a dose of 2.5mg/kg can also significantly inhibit the rat ankle odema induced by carrageenan and egg white.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Edema/drug therapy , Insect Hormones/therapeutic use , Materia Medica/therapeutic use , Moths , Animals , Anti-Inflammatory Agents, Non-Steroidal/isolation & purification , Carrageenan , Croton Oil , Edema/chemically induced , Female , Insect Hormones/isolation & purification , Male , Materia Medica/chemistry , Mice , Mice, Inbred C57BL , Moths/chemistry , Ovalbumin , Rats , Rats, Sprague-DawleySubject(s)
Chagas Disease/drug therapy , Homeopathy/methods , Parasitemia/drug therapy , Phosphorus/pharmacology , Phytotherapy/methods , Plant Extracts/therapeutic use , Trypanosoma cruzi/drug effects , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Mice , Mice, Inbred C57BL , Parasitemia/virology , Plant Extracts/pharmacology , Random AllocationABSTRACT
The control of melanogenesis is an important strategy in the treatment of abnormal skin pigmentation for cosmetic purposes. The aim of the present study was to investigate the anti-melanogenic effect of Asterina pectinifera (A. pectinifera) extracts by cell-free mushroom tyrosinase assay, cellular tyrosinase assay, melanin content assay and the analysis of related protein expression in melan-a cells. A. pectinifera was extracted with 80% methanol (80-MAP) and further fractionated with hexane (He-AP) and ethyl acetate (EA-AP). In addition, the enzyme extract (En-AP) of A. pectinifera, to which protease was added, was processed. EA-AP and En-AP among A. pectinifera extracts showed strong inhibitory activity against the cell-free mushroom tyrosinase activity. EA-AP and En-AP induced significant inhibition of melanin production and cellular tyrosinase activity. In the action of EA-AP and En-AP on melanogenesis, they reduced the expression of melanogenic genes and proteins including tyrosinase, tyrosinase-related protein-1 (TRP-1) and dopachrome tautomerase (Dct). These results showed that EA-AP and En-AP inhibited melanogenesis by reducing tyrosinase activity and melanin production via subsequent downregulation of tyrosinase-related proteins. The overall results suggest that EA-AP and En-AP among A. pectinifera extracts may be promising candidates for the treatment of hyperpigmentation disorder and useful for self-tanning cosmetic products.
Subject(s)
Asterina/chemistry , Materia Medica/pharmacology , Melanins/biosynthesis , Melanocytes/drug effects , Monophenol Monooxygenase/metabolism , Animals , Cell Line , Cell Survival , Intramolecular Oxidoreductases/antagonists & inhibitors , Intramolecular Oxidoreductases/genetics , Intramolecular Oxidoreductases/metabolism , Melanins/antagonists & inhibitors , Melanocytes/enzymology , Mice , Mice, Inbred C57BL , Monophenol Monooxygenase/antagonists & inhibitors , Monophenol Monooxygenase/genetics , Oxidoreductases/antagonists & inhibitors , Oxidoreductases/genetics , Oxidoreductases/metabolism , Skin Pigmentation/drug effectsABSTRACT
Intranasal medications are used to treat various nasal disorders. However, their effects on olfaction remain unknown. Zicam (zinc gluconate; Matrixx Initiatives, Inc), a homeopathic substance marketed to alleviate cold symptoms, has been implicated in olfactory dysfunction. Here, we investigated Zicam and several common intranasal agents for their effects on olfactory function. Zicam was the only substance that showed significant cytotoxicity in both mouse and human nasal tissue. Specifically, Zicam-treated mice had disrupted sensitivity of olfactory sensory neurons to odorant stimulation and were unable to detect novel odorants in behavioral testing. These findings were long-term as no recovery of function was observed after two months. Finally, human nasal explants treated with Zicam displayed significantly elevated extracellular lactate dehydrogenase levels compared to saline-treated controls, suggesting severe necrosis that was confirmed on histology. Our results demonstrate that Zicam use could irreversibly damage mouse and human nasal tissue and may lead to significant smell dysfunction.